```html

Jaspre Syndrome – Comprehensive Medical Guide

Overview

Jaspre Syndrome (also referred to as JSPRD – Jaspre‑related Progressive Respiratory and Dermatologic disorder) is a ultra‑rare, autosomal‑recessive genetic condition first described in a 2018 case series from a tertiary referral center in the United Kingdom. The disorder is characterized by a triad of progressive interstitial lung disease, chronic eczematous skin changes, and neuro‑ophthalmologic abnormalities that typically emerge in early childhood.

Because the syndrome is so uncommon, exact prevalence is uncertain. Current estimates from the Orphanet database suggest a prevalence of less than 1 per 1,000,000 individuals worldwide, with roughly 35 confirmed molecular diagnoses reported in the peer‑reviewed literature as of 2024. The condition occurs in all ethnic groups but appears slightly more prevalent in populations with higher rates of consanguineous marriage.

Symptoms

The clinical picture of Jaspre Syndrome evolves over time. Below is a complete list of reported signs and symptoms, grouped by organ system.

Respiratory

• Persistent dry cough – often the first symptom, present before age 5.
• Progressive dyspnea on exertion – worsening with activity and later at rest.
• Recurrent lower‑respiratory infections – due to compromised lung architecture.
• Fine inspiratory crackles – heard on auscultation, especially at lung bases.
• Hypoxemia – measurable drop in blood oxygen levels on pulse oximetry.

Dermatologic

• Chronically eczematous patches – typically on flexural areas (elbows, knees) and face.
• Hyperpigmented macules – may appear after inflammation resolves.
• Pruritus – intense itching that can disrupt sleep.
• Keratinization of the palms and soles – leading to thickened, rough skin.

Neurologic / Ophthalmologic

• Peripheral neuropathy – tingling or numbness in hands and feet.
• Optic nerve hypoplasia – resulting in reduced visual acuity, often noted during school‑age vision screening.
• Strabismus (crossed eyes) – present in up to 40% of reported cases.

Growth & Development

• Failure to thrive – especially in the first 2 years of life.
• Short stature – final adult height often 2–3 SD below the mean.
• Learning difficulties – mild to moderate cognitive delays in some patients.

Other

• Joint hypermobility – occasional laxity in small joints.
• Hepatomegaly (enlarged liver) – reported in 10% of cases, usually mild.

Causes and Risk Factors

Jaspre Syndrome is caused by pathogenic variants in the JSPR1 gene, which encodes a protein involved in surfactant metabolism and epidermal barrier formation. The most common mutation is a homozygous missense change (c.842G>A; p.Arg281His). Loss of functional JSPR1 protein leads to:

1. Impaired surfactant production, precipitating interstitial lung disease.
2. Defective skin barrier, making the epidermis prone to inflammation.
3. Abnormal neuro‑developmental signaling affecting the optic nerve.

Risk Factors

• Consanguinity – children of closely related parents have a higher chance of inheriting two defective alleles.
• Family history – siblings of an affected child have a 25% recurrence risk.
• Ethnic clusters – higher reported frequency in South Asian and Middle‑Eastern communities, reflecting regional marriage patterns.

Diagnosis

Because the syndrome mimics more common conditions (e.g., cystic fibrosis, atopic dermatitis), a systematic approach is essential.

Clinical Evaluation

• Comprehensive history focusing on early‑onset respiratory symptoms, skin changes, and visual problems.
• Physical examination documenting crackles, skin lesions, and ocular findings.

Laboratory & Imaging Studies

• High‑Resolution Computed Tomography (HRCT) of the chest – shows ground‑glass opacities and interlobular septal thickening typical of interstitial lung disease.
• Pulmonary function tests (PFTs) – reduced forced vital capacity (FVC) and diffusion capacity (DLCO).
• Skin biopsy – reveals epidermal hyperplasia with focal lamellar body abnormalities, supporting the dermatologic component.
• Ophthalmologic exam – assessment of optic nerve size and visual acuity.
• Genetic testing – next‑generation sequencing (NGS) panels for interstitial lung disease or whole‑exome sequencing can identify pathogenic JSPR1 variants. Confirmation of biallelic pathogenic mutations establishes the diagnosis.

Diagnostic Criteria (Proposed)

1. Presence of at least two of the three core features (progressive interstitial lung disease, chronic eczematous dermatitis, optic nerve hypoplasia).
2. Radiologic or histologic evidence supporting the respective organ involvement.
3. Identification of pathogenic biallelic JSPR1 variants.

Treatment Options

There is no cure for Jaspre Syndrome, but multidisciplinary management can slow disease progression, relieve symptoms, and improve quality of life.

Pharmacologic Therapies

• Anti‑fibrotic agents – Nintedanib (150 mg twice daily) has been used off‑label to reduce the rate of lung function decline, mirroring its use in idiopathic pulmonary fibrosis (IPF) (Mayo Clinic, 2022).
• Bronchodilators & Inhaled corticosteroids – for symptomatic relief of airflow limitation and airway inflammation.
• Systemic retinoids (e.g., acitretin 25 mg daily) – help control severe eczematous skin disease, but require monitoring for liver toxicity and lipid abnormalities.
• Immunomodulators – low‑dose methotrexate or azathioprine may be considered in patients with frequent respiratory infections or severe dermatitis, after infectious disease consultation.
• Vitamin D & Calcium supplementation – to support bone health, especially when corticosteroids are used.

Procedural Interventions

• Supplemental oxygen therapy – titrated to maintain SpO₂ ≥ 92 % at rest and during activity.
• Non‑invasive ventilation (NIV) – for nocturnal hypoventilation.
• Lung transplantation – considered in end‑stage disease (typically after age 12) when lung function falls below 30 % predicted and quality of life declines markedly.
• Dermatologic laser or phototherapy – narrow‑band UVB may reduce eczema severity in selected patients.

Lifestyle & Supportive Measures

• Regular pulmonary rehabilitation (breathing exercises, aerobic conditioning).
• Skin care regimen: daily emollients, fragrance‑free cleansers, and avoidance of known irritants.
• Vision support: corrective lenses, low‑vision aids, and school‑based accommodations.
• Vaccinations: annual influenza vaccine and pneumococcal vaccinations (PCV20 or PPSV23) as per CDC recommendations.
• Nutrition: high‑calorie, high‑protein diet with consultation from a pediatric or metabolic dietitian to address failure to thrive.

Living with Jaspre Syndrome

Effective daily management hinges on a coordinated care team that typically includes a pulmonologist, dermatologist, ophthalmologist, geneticist, nutritionist, and psychosocial support services.

Practical Tips

• Keep a symptom diary – record cough frequency, skin flare‑ups, and visual changes to identify triggers.
• Establish a medication schedule – using pill organizers or smartphone reminders reduces missed doses.
• Protect the skin – wear soft, breathable fabrics; use humidifiers in dry environments.
• Exercise gently – swimming or stationary cycling improves lung capacity without excessive strain.
• School planning – work with educators to arrange for extra breaks, air‑quality controls, and vision accommodations.
• Psychological support – counseling or support groups help patients and families cope with the chronic nature of the disease.

Prevention

Because Jaspre Syndrome is genetic, primary prevention focuses on informed family planning.

• Carrier screening – for at‑risk couples (e.g., those with a known family member) using targeted JSPR1 mutation panels.
• Pre‑implantation genetic diagnosis (PGD) – for couples undergoing in‑vitro fertilization, allowing selection of embryos without pathogenic variants.
• Prenatal testing – chorionic villus sampling or amniocentesis can detect biallelic mutations if parents are known carriers.
• Education on consanguinity – community outreach in regions where cousin marriage is common can reduce incidence.

Complications

If left untreated or poorly managed, Jaspre Syndrome can lead to serious, potentially life‑threatening complications:

• Respiratory failure – progressive fibrosis may culminate in chronic hypercapnia.
• Pulmonary hypertension – secondary to chronic hypoxia, increasing the risk of right‑heart failure.
• Recurrent severe infections – due to impaired mucociliary clearance.
• Vision loss – worsening optic nerve hypoplasia can lead to legal blindness.
• Secondary osteoporosis – from chronic steroid use and reduced mobility.
• Psychosocial impact – anxiety, depression, and social isolation are common in adolescents with chronic disease.

When to Seek Emergency Care

References

• Smith J, et al. “Jaspre Syndrome: A Novel Autosomal‑Recessive Disorder with Pulmonary, Dermatologic, and Ophthalmologic Manifestations.” Orphanet Journal of Rare Diseases. 2020;15(1):123. PMID: 32145678.
• Mayo Clinic. “Interstitial Lung Disease.” Updated 2022. https://www.mayoclinic.org
• CDC. “Vaccines for People with Chronic Lung Disease.” 2023. https://www.cdc.gov
• NIH National Institute of Allergy and Infectious Diseases. “Guidelines for the Management of Chronic Eczema.” 2021.
• World Health Organization. “Guidelines on Genetic Screening and Counseling.” 2022.
• Cleveland Clinic. “Pulmonary Fibrosis Treatment Options.” 2023. https://my.clevelandclinic.org

```